| Fonds | 2026/Q1 | 2025/Q4 | 2025/Q3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Investment ($) | QoQ ($) | QoQ (%) | Investment ($) | QoQ ($) | QoQ (%) | |
| 1.256.685.557 $ | -30.476.102 $ | +0,6 % | 1.389.213.133 $ | +350.173.600 $ | +38,9 % | 945.902.270 $ | +382.310.733 $ | +66,4 % | |
| RA CAPITAL MANAGEMENT, L.P. | 397.093.254 $ | -10.400.297 $ | -2,6 % | 407.493.551 $ | +100.296.631 $ | +32,6 % | 307.196.920 $ | +125.970.583 $ | +69,5 % |
| TPG GP A, LLC | 260.383.027 $ | -17.104.710 $ | -6,2 % | 277.487.737 $ | +79.118.405 $ | +39,9 % | 198.369.332 $ | +81.344.241 $ | +69,5 % |
| ORBIMED ADVISORS LLC | 141.545.843 $ | -4.980.644 $ | -3,4 % | 146.526.487 $ | +37.563.643 $ | +34,5 % | 108.962.844 $ | +44.681.805 $ | +69,5 % |
| VIKING GLOBAL INVESTORS LP | 128.094.806 $ | -3.354.940 $ | -2,6 % | 131.449.746 $ | +37.479.473 $ | +39,9 % | 93.970.273 $ | +38.533.883 $ | +69,5 % |
| Atlas Venture Life Science Advisors, LLC | 120.093.684 $ | -3.145.382 $ | -2,6 % | 123.239.066 $ | +16.906.417 $ | +15,9 % | 106.332.649 $ | +42.241.402 $ | +65,9 % |
| Enavate Sciences GP, LLC | 99.344.223 $ | -2.601.931 $ | -2,6 % | 101.946.154 $ | +29.067.292 $ | +39,9 % | 72.878.862 $ | +29.885.041 $ | +69,5 % |
| JPMORGAN CHASE & CO | 50.677.035 $ | -7.514.355 $ | -12,9 % | 58.191.390 $ | +19.653.778 $ | +51,0 % | |||
| JENNISON ASSOCIATES LLC | 58.179.411 $ | +12.296.875 $ | +26,8 % | ||||||
| BlackRock, Inc. | 51.951.309 $ | -1.185.073 $ | -2,2 % | 53.136.382 $ | +28.296.550 $ | +113,9 % | |||
| VANGUARD GROUP INC | 48.748.883 $ | +15.128.724 $ | +45,0 % | ||||||
| PERCEPTIVE ADVISORS LLC | 48.508.092 $ | +13.830.820 $ | +39,9 % | ||||||
| 1.256.685.557 $ | -30.476.102 $ | +0,6 % | 1.389.213.133 $ | +350.173.600 $ | +38,9 % | 945.902.270 $ | +382.310.733 $ | +66,4 % | |